Bonanza of New Treatment Regimens for Multiple Myeloma: What is Right for My Patient?

A uniform treatment approach cannot be applied to all patients. Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigate through the complex and evolving treatment landscape of multiple myeloma (MM). Health care providers need education about how to individualize treatment plans in this complex environment to help them make the best decisions in their own practices and improve the outcomes of patients with newly diagnosed as well as those with relapsed/refractory MM. 

This information was originally presented at the NCCN 2020 Virtual Congress: Hematologic Malignancies™  held on October 9-10, 2020.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Utilize evidence-based strategies to inform optimal treatment of patients with newly diagnosed multiple myeloma (MM) taking individual patient-characteristics into consideration.
  • Evaluate clinical data supporting the newer treatment options for patients with relapsed/refractory MM.
  • Review novel emerging agents for treatment of relapsed/refractory MM.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Jazz Pharmaceuticals, Inc.
  • Novartis
  • Pharmacyclics LLC, an Abbvie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.
  • Seattle Genetics, Inc. 
  • Takeda

This activity is supported by independent educational grants from:

  • Abbvie
  • Astellas
  • Incyte

This activity is supported by an independent medical education grant from Bristol Myers Squibb.

Course summary
Available credit: 
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Course opens: 
10/30/2020
Course expires: 
10/30/2021
Cost:
$0.00

Shaji K. Kumar, MD
Mayo Clinic Cancer Center

 

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions 

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Shaji K. Kumar, MD 
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb Company: Grant/Research Support
CARsgen Therapeutics: Grant/Research Support
Celgene Corporation: Grant/Research Support; Scientific Advisor
Cellectar Biosciences: Consulting Fee
GeneCentrix, Inc.: Consulting Fee
Genentech, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Kite Pharma: Grant/Research Support
MedImmune Inc.: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Oncopeptides: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
TeneBio: Grant/Research Support

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Leadership listed below discloses no relevant financial relationships: 
Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR 

The NCCN Leadership listed below discloses the following relevant financial relationships: 
Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer Keller; Rashmi Kumar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.50 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.05 CEUs) of continuing education credit. UAN: JA4008196-0000-20-126-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: